David Brunell
Overview
Explore the profile of David Brunell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
163
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Inoue A, Robinson F, Minelli R, Tomihara H, Rizi B, Rose J, et al.
Gastroenterology
. 2021 Mar;
161(1):196-210.
PMID: 33745946
Background & Aims: Understanding the mechanisms by which tumors adapt to therapy is critical for developing effective combination therapeutic approaches to improve clinical outcomes for patients with cancer. Methods: To...
2.
Wadsworth P, Folorunso O, Nguyen N, Singh A, DAmico D, Powell R, et al.
Sci Rep
. 2019 Nov;
9(1):16890.
PMID: 31729429
Multiple voltage-gated Na (Nav) channelopathies can be ascribed to subtle changes in the Nav macromolecular complex. Fibroblast growth factor 14 (FGF14) is a functionally relevant component of the Nav1.6 channel...
3.
Huang L, Brunell D, Stephan C, Mancuso J, Yu X, He B, et al.
Bioinformatics
. 2019 Feb;
35(19):3709-3717.
PMID: 30768150
Motivation: Drug combinations that simultaneously suppress multiple cancer driver signaling pathways increase therapeutic options and may reduce drug resistance. We have developed a computational systems biology tool, DrugComboExplorer, to identify...
4.
Kalu N, Mazumdar T, Peng S, Tong P, Shen L, Wang J, et al.
Cancer Lett
. 2018 May;
431:64-72.
PMID: 29807113
To address the unmet need for effective biomarker-driven targeted therapy for human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC) and cervical cancer, we conducted a high-throughput drug screen...
5.
Dong J, Park S, Nguyen N, Ezhilarasan R, Martinez-Ledesma E, Wu S, et al.
Oncotarget
. 2018 Mar;
9(12):10497-10509.
PMID: 29535822
Background: Despite the availability of hundreds of cancer drugs, there is insufficient data on the efficacy of these drugs on the extremely heterogeneous tumor cell populations of glioblastoma (GBM). Results:...
6.
Kogiso M, Qi L, Lindsay H, Huang Y, Zhao X, Liu Z, et al.
Oncotarget
. 2017 Nov;
8(50):87455-87471.
PMID: 29152094
To identify cellular and molecular changes that driver pediatric low grade glioma (PLGG) progression, we analyzed putative cancer stem cells (CSCs) and evaluated key biological changes in a novel and...
7.
Brunell D, Sagher D, Kesaraju S, Brot N, Weissbach H
Drug Metab Dispos
. 2011 Mar;
39(6):1014-21.
PMID: 21383205
Sulindac is a nonsteroidal, anti-inflammatory drug (NSAID) that has also been studied for its anticancer activity. Recent studies suggest that sulindac and its metabolites act by sensitizing cancer cells to...
8.
Brunell D, Weissbach H, Hodder P, Brot N
Assay Drug Dev Technol
. 2010 Jun;
8(5):615-20.
PMID: 20515413
The methionine sulfoxide reductase (Msr) system has been shown to play an important role in protecting cells against oxidative damage. This family of enzymes can repair damage to proteins resulting...
9.
Sagher D, Brunell D, Brot N, Vallee B, Weissbach H
J Biol Chem
. 2006 Aug;
281(42):31184-7.
PMID: 16916796
In a recent study on the reducing requirement for the methionine sulfoxide reductases (Msr) (Sagher, D., Brunell, D., Hejtmancik, J. F., Kantorow, M., Brot, N. & Weissbach, H. (2006) Proc....
10.
Sagher D, Brunell D, Hejtmancik J, Kantorow M, Brot N, Weissbach H
Proc Natl Acad Sci U S A
. 2006 Jun;
103(23):8656-61.
PMID: 16735467
It has been generally accepted, primarily from studies on methionine sulfoxide reductase (Msr) A, that the biological reducing agent for the members of the Msr family is reduced thioredoxin (Trx),...